Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial - PubMed (original) (raw)
Clinical Trial
. 2003 Nov 19;290(19):2588-98.
doi: 10.1001/jama.290.19.2588.
Michel Wolff, Jean-Yves Fagon, Sylvie Chevret, Franck Thomas, Delphine Wermert, Eva Clementi, Jesus Gonzalez, Dominique Jusserand, Pierre Asfar, Dominique Perrin, Fabienne Fieux, Sylvie Aubas; PneumA Trial Group
Affiliations
- PMID: 14625336
- DOI: 10.1001/jama.290.19.2588
Clinical Trial
Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial
Jean Chastre et al. JAMA. 2003.
Abstract
Context: The optimal duration of antimicrobial treatment for ventilator-associated pneumonia (VAP) is unknown. Shortening the length of treatment may help to contain the emergence of multiresistant bacteria in the intensive care unit (ICU).
Objective: To determine whether 8 days is as effective as 15 days of antibiotic treatment of patients with microbiologically proven VAP.
Design, setting, and participants: Prospective, randomized, double-blind (until day 8) clinical trial conducted in 51 French ICUs. A total of 401 patients diagnosed as having developed VAP by quantitative culture results of bronchoscopic specimens and who had received initial appropriate empirical antimicrobial therapy were enrolled between May 1999 and June 2002.
Intervention: A total of 197 patients were randomly assigned to receive 8 days and 204 to receive 15 days of therapy with an antibiotic regimen selected by the treating physician.
Main outcome measures: Primary outcome measures-death from any cause, microbiologically documented pulmonary infection recurrence, and antibiotic-free days-were assessed 28 days after VAP onset and analyzed on an intent-to-treat basis.
Results: Compared with patients treated for 15 days, those treated for 8 days had neither excess mortality (18.8% vs 17.2%; difference, 1.6%; 90% confidence interval [CI], -3.7% to 6.9%) nor more recurrent infections (28.9% vs 26.0%; difference, 2.9%; 90% CI, -3.2% to 9.1%), but they had more mean (SD) antibiotic-free days (13.1 [7.4] vs 8.7 [5.2] days, P<.001). The number of mechanical ventilation-free days, the number of organ failure-free days, the length of ICU stay, and mortality rates on day 60 for the 2 groups did not differ. Although patients with VAP caused by nonfermenting gram-negative bacilli, including Pseudomonas aeruginosa, did not have more unfavorable outcomes when antimicrobial therapy lasted only 8 days, they did have a higher pulmonary infection-recurrence rate compared with those receiving 15 days of treatment (40.6% vs 25.4%; difference, 15.2%, 90% CI, 3.9%-26.6%). Among patients who developed recurrent infections, multiresistant pathogens emerged less frequently in those who had received 8 days of antibiotics (42.1% vs 62.0% of pulmonary recurrences, P =.04).
Conclusions: Among patients who had received appropriate initial empirical therapy, with the possible exception of those developing nonfermenting gram-negative bacillus infections, comparable clinical effectiveness against VAP was obtained with the 8- and 15-day treatment regimens. The 8-day group had less antibiotic use.
Comment in
- Eight days vs 15 days of antibiotics for ventilator-associated pneumonia.
Nicastri E. Nicastri E. JAMA. 2004 Feb 18;291(7):820; author reply 820. doi: 10.1001/jama.291.7.820-a. JAMA. 2004. PMID: 14970057 No abstract available. - An antibiotic regimen for 8 days was as effective as one for 15 days in ventilator-associated pneumonia.
Marshall JC. Marshall JC. ACP J Club. 2004 Sep-Oct;141(2):30. ACP J Club. 2004. PMID: 15341450 No abstract available.
Similar articles
- Impact of the duration of antibiotics on clinical events in patients with Pseudomonas aeruginosa ventilator-associated pneumonia: study protocol for a randomized controlled study.
Bouglé A, Foucrier A, Dupont H, Montravers P, Ouattara A, Kalfon P, Squara P, Simon T, Amour J; iDIAPASON study group. Bouglé A, et al. Trials. 2017 Jan 23;18(1):37. doi: 10.1186/s13063-017-1780-3. Trials. 2017. PMID: 28114979 Free PMC article. Clinical Trial. - Implementation of bronchoscopic techniques in the diagnosis of ventilator-associated pneumonia to reduce antibiotic use.
Bonten MJ, Bergmans DC, Stobberingh EE, van der Geest S, De Leeuw PW, van Tiel FH, Gaillard CA. Bonten MJ, et al. Am J Respir Crit Care Med. 1997 Dec;156(6):1820-4. doi: 10.1164/ajrccm.156.6.9610117. Am J Respir Crit Care Med. 1997. PMID: 9412561 - Does bronchoalveolar lavage enhance our ability to treat ventilator-associated pneumonia in a trauma-burn intensive care unit?
Wahl WL, Franklin GA, Brandt MM, Sturm L, Ahrns KS, Hemmila MR, Arbabi S. Wahl WL, et al. J Trauma. 2003 Apr;54(4):633-8; discussion 638-9. doi: 10.1097/01.TA.0000057229.70607.F2. J Trauma. 2003. PMID: 12707523 - Diagnosis and treatment of ventilator-associated pneumonia.
Porzecanski I, Bowton DL. Porzecanski I, et al. Chest. 2006 Aug;130(2):597-604. doi: 10.1378/chest.130.2.597. Chest. 2006. PMID: 16899866 Review. - Bench-to-bedside review: Therapeutic options and issues in the management of ventilator-associated bacterial pneumonia.
Rello J. Rello J. Crit Care. 2005 Jun;9(3):259-65. doi: 10.1186/cc3014. Epub 2004 Nov 30. Crit Care. 2005. PMID: 15987380 Free PMC article. Review.
Cited by
- Challenging management dogma where evidence is non-existent, weak, or outdated: part II.
Hofmaenner DA, Singer M. Hofmaenner DA, et al. Intensive Care Med. 2024 Sep 25. doi: 10.1007/s00134-024-07634-x. Online ahead of print. Intensive Care Med. 2024. PMID: 39320462 Review. - Duration of antibiotic therapy for multidrug resistant Pseudomonas aeruginosa pneumonia: is shorter truly better?
Truong CN, Chin-Beckford N, Vega A, DeRonde K, Simon J, Abbo LM, Rosa R, Vu CA. Truong CN, et al. BMC Infect Dis. 2024 Sep 3;24(1):911. doi: 10.1186/s12879-024-09600-w. BMC Infect Dis. 2024. PMID: 39227823 Free PMC article. - Key summary of German national guideline for adult patients with nosocomial pneumonia- Update 2024 Funding number at the Federal Joint Committee (G-BA): 01VSF22007.
Rademacher J, Ewig S, Grabein B, Nachtigall I, Abele-Horn M, Deja M, Gaßner M, Gatermann S, Geffers C, Gerlach H, Hagel S, Heußel CP, Kluge S, Kolditz M, Kramme E, Kühl H, Panning M, Rath PM, Rohde G, Schaaf B, Salzer HJF, Schreiter D, Schweisfurth H, Unverzagt S, Weigand MA, Welte T, Pletz MW. Rademacher J, et al. Infection. 2024 Aug 8. doi: 10.1007/s15010-024-02358-y. Online ahead of print. Infection. 2024. PMID: 39115698 - An investigation of broad-spectrum antibiotic-induced liver injury based on the FDA Adverse Event Reporting System and retrospective observational study.
Shiraishi C, Kato H, Ogura T, Iwamoto T. Shiraishi C, et al. Sci Rep. 2024 Aug 6;14(1):18221. doi: 10.1038/s41598-024-69279-6. Sci Rep. 2024. PMID: 39107511 Free PMC article. - Optimising antibiotic exposure by customising the duration of treatment for respiratory tract infections based on patient needs in primary care.
Llor C, Frimodt-Møller N, Miravitlles M, Kahlmeter G, Bjerrum L. Llor C, et al. EClinicalMedicine. 2024 Jul 3;74:102723. doi: 10.1016/j.eclinm.2024.102723. eCollection 2024 Aug. EClinicalMedicine. 2024. PMID: 39070175 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical